189 related articles for article (PubMed ID: 32310023)
1. Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues.
Conner KP; Pastuskovas CV; Soto M; Thomas VA; Wagner M; Rock DA
MAbs; 2020; 12(1):1746520. PubMed ID: 32310023
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).
Ahlberg J; Giragossian C; Li H; Myzithras M; Raymond E; Caviness G; Grimaldi C; Brown SE; Perez R; Yang D; Kroe-Barrett R; Joseph D; Pamulapati C; Coble K; Ruus P; Woska JR; Ganesan R; Hansel S; Mbow ML
MAbs; 2019 Jul; 11(5):956-964. PubMed ID: 31068073
[TBL] [Abstract][Full Text] [Related]
3. Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.
Ganesan R; Raymond EL; Mennerich D; Woska JR; Caviness G; Grimaldi C; Ahlberg J; Perez R; Roberts S; Yang D; Jerath K; Truncali K; Frego L; Sepulveda E; Gupta P; Brown SE; Howell MD; Canada KA; Kroe-Barrett R; Fine JS; Singh S; Mbow ML
MAbs; 2017 Oct; 9(7):1143-1154. PubMed ID: 28726542
[TBL] [Abstract][Full Text] [Related]
4. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
[TBL] [Abstract][Full Text] [Related]
5. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
6. Development and Translational Application of a Minimal Physiologically Based Pharmacokinetic Model for a Monoclonal Antibody against Interleukin 23 (IL-23) in IL-23-Induced Psoriasis-Like Mice.
Chen X; Jiang X; Doddareddy R; Geist B; McIntosh T; Jusko WJ; Zhou H; Wang W
J Pharmacol Exp Ther; 2018 Apr; 365(1):140-155. PubMed ID: 29420255
[TBL] [Abstract][Full Text] [Related]
7. Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys.
Vexler V; Yu L; Pamulapati C; Garrido R; Grimm HP; Sriraman P; Bohini S; Schraeml M; Singh U; Brandt M; Ries S; Ma H; Klumpp K; Ji C
MAbs; 2013; 5(5):776-86. PubMed ID: 23924796
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the In Vivo Performance of a Monoclonal Antibody to Neutralize Its Soluble Target at the Site of Action in a Mouse Collagen-Induced Arthritis Model.
Wang W; McIntosh TS; Jiang X; Doddareddy R; Dell EC; Zhou H
Pharm Res; 2016 Apr; 33(4):1040-9. PubMed ID: 26718954
[TBL] [Abstract][Full Text] [Related]
9. IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis.
Su Z; Paulsboe S; Wetter J; Salte K; Kannan A; Mathew S; Horowitz A; Gerstein C; Namovic M; Todorović V; Seagal J; Edelmayer RM; Viner M; Rinaldi L; Zhou L; Leys L; Huang S; Wang L; Sadhukhan R; Honore P; McGaraughty S; Scott VE
Exp Dermatol; 2019 Feb; 28(2):113-120. PubMed ID: 30417427
[TBL] [Abstract][Full Text] [Related]
10. Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis.
Chen X; Jiang X; Jusko WJ; Zhou H; Wang W
J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):291-304. PubMed ID: 27119518
[TBL] [Abstract][Full Text] [Related]
11. Target-mediated drug disposition model for drugs that bind to more than one target.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
[TBL] [Abstract][Full Text] [Related]
12. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
[TBL] [Abstract][Full Text] [Related]
13. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
[TBL] [Abstract][Full Text] [Related]
14. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action.
Sheridan D; Yu ZX; Zhang Y; Patel R; Sun F; Lasaro MA; Bouchard K; Andrien B; Marozsan A; Wang Y; Tamburini P
PLoS One; 2018; 13(4):e0195909. PubMed ID: 29649283
[TBL] [Abstract][Full Text] [Related]
15. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
Glassman PM; Chen Y; Balthasar JP
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
[TBL] [Abstract][Full Text] [Related]
16. Assessments of antibody biodistribution.
Glassman PM; Abuqayyas L; Balthasar JP
J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S29-38. PubMed ID: 25707961
[TBL] [Abstract][Full Text] [Related]
17. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
18. A novel immunoassay to measure total serum lymphotoxin-α levels in the presence of an anti-LTα therapeutic antibody.
Young J; Nguyen A; Qiu ZJ; Ying Y; Gao X; Reed C; Chuntharapai A; Deng R; Lutman J; Grogan J; Wong WL; DeForge L
J Immunol Methods; 2015 Sep; 424():91-9. PubMed ID: 26009247
[TBL] [Abstract][Full Text] [Related]
19. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations.
Grimm HP
J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):407-20. PubMed ID: 19728050
[TBL] [Abstract][Full Text] [Related]
20. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human.
Shah DK; Betts AM
MAbs; 2013; 5(2):297-305. PubMed ID: 23406896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
